(-)-Epigallocatechin-3-gallate suppresses liver metastasis of human colorectal cancer

Maruyama,Takehito; Murata,Soichiro; Nakayama,Ken; Sano,Naoki; Ogawa,Koichi; Nowatari,Takeshi; Tamura,Takafumi; Nozaki,Reiji; Fukunaga,Kiyoshi; Ohkohchi,Nobuhiro

doi:10.3892/or.2013.2925

(-)-Epigallocatechin-3-gallate suppresses liver metastasis of human colorectal cancer

Authors:
- Takehito Maruyama
- Soichiro Murata
- Ken Nakayama
- Naoki Sano
- Koichi Ogawa
- Takeshi Nowatari
- Takafumi Tamura
- Reiji Nozaki
- Kiyoshi Fukunaga
- Nobuhiro Ohkohchi
View Affiliations

Affiliations: Department of Surgery, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
Published online on: December 13, 2013 https://doi.org/10.3892/or.2013.2925
Pages: 625-633

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

(-)-Epigallocatechin-3-gallate (EGCG), the major constituent of green tea, has been shown to inhibit cell proliferation and induce apoptosis in several types of human tumors. The most common site of distant metastases in colorectal cancer is the liver. However, no previous studies have reported the ability of EGCG to suppress liver metastases of human colorectal cancer. The aim of the present study was to elucidate the potential use of EGCG as chemotherapy targeting liver metastases of human colorectal cancer. To assess the effect of EGCG on human colorectal cancer cell lines, RKO and HCT116, cell viability, cell proliferation and apoptosis were measured by cell counting kit-8, BrdU assay and TUNEL staining, respectively. Protein and gene expression were measured by western blot analysis and RT-PCR analysis, respectively. EGCG inhibited cell proliferation and induced apoptosis. EGCG dephosphorylated constitutively activated Akt and increased the activation of p38. EGCG also decreased the expression of vascular endothelial growth factor receptor 2. Additionally, the ability of EGCG to prevent the development of liver metastases of RKO tumors was evaluated in SCID mice. EGCG suppressed angiogenesis and induced apoptosis in liver metastases without associated body weight loss or hepatotoxicity. Furthermore, the liver metastatic area was significantly reduced by EGCG administration. Our findings indicate that EGCG may be useful in the treatment of liver metastases of human colorectal cancer.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J and Bouvier AM: Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 244:254–259. 2006. View Article : Google Scholar : PubMed/NCBI
3	Hughes KS, Rosenstein RB, Songhorabodi S, et al: Resection of the liver for colorectal carcinoma metastases. A multi-institutional study of long-term survivors. Dis Colon Rectum. 31:1–4. 1988. View Article : Google Scholar : PubMed/NCBI
4	Scheele J, Stang R, Altendorf-Hofmann A and Paul M: Resection of colorectal liver metastases. World J Surg. 19:59–71. 1995. View Article : Google Scholar : PubMed/NCBI
5	Kato T, Yasui K, Hirai T, et al: Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum. 46:S22–S31. 2003.
6	Yamada H, Katoh H, Kondo S, Okushiba S and Morikawa T: Repeat hepatectomy for recurrent hepatic metastases from colorectal cancer. Hepatogastroenterology. 48:828–830. 2001.PubMed/NCBI
7	Scheer MG, Sloots CE, van der Wilt GJ and Ruers TJ: Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol. 19:1829–1835. 2008. View Article : Google Scholar : PubMed/NCBI
8	Dy GK, Hobday TJ, Nelson G, et al: Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: north central cancer treatment group review of 3811 patients, n0144. Clin Colorectal Cancer. 8:88–93. 2009. View Article : Google Scholar
9	Venook A: Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist. 10:250–261. 2005. View Article : Google Scholar : PubMed/NCBI
10	Cabrera C, Artacho R and Gimenez R: Beneficial effects of green tea: a review. J Am Coll Nutr. 25:79–99. 2006. View Article : Google Scholar : PubMed/NCBI
11	Ji BT, Chow WH, Hsing AW, et al: Green tea consumption and the risk of pancreatic and colorectal cancers. Int J Cancer. 70:255–258. 1997. View Article : Google Scholar : PubMed/NCBI
12	Yang G, Shu XO, Li H, et al: Prospective cohort study of green tea consumption and colorectal cancer risk in women. Cancer Epidemiol Biomarkers Prev. 16:1219–1223. 2007. View Article : Google Scholar : PubMed/NCBI
13	Cabrera C, Gimenez R and Lopez MC: Determination of tea components with antioxidant activity. J Agric Food Chem. 51:4427–4435. 2003. View Article : Google Scholar : PubMed/NCBI
14	Du GJ, Zhang Z, Wen XD, et al: Epigallocatechin gallate (EGCG) is the most effective cancer chemopreventive polyphenol in green tea. Nutrients. 4:1679–1691. 2012. View Article : Google Scholar : PubMed/NCBI
15	Shimizu M, Adachi S, Masuda M, Kozawa O and Moriwaki H: Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases. Mol Nutr Food Res. 55:832–843. 2011. View Article : Google Scholar : PubMed/NCBI
16	Chen C, Shen G, Hebbar V, Hu R, Owuor ED and Kong AN: Epigallocatechin-3-gallate-induced stress signals in HT-29 human colon adenocarcinoma cells. Carcinogenesis. 24:1369–1378. 2003. View Article : Google Scholar : PubMed/NCBI
17	Shimizu M, Shirakami Y, Sakai H, et al: (−)-Epigallocatechin gallate inhibits growth and activation of the VEGF/VEGFR axis in human colorectal cancer cells. Chem Biol Interact. 185:247–252. 2010.
18	Tran PL, Kim SA, Choi HS, Yoon JH and Ahn SG: Epigallocatechin-3-gallate suppresses the expression of HSP70 and HSP90 and exhibits anti-tumor activity in vitro and in vivo. BMC Cancer. 10:2762010. View Article : Google Scholar : PubMed/NCBI
19	Jin H, Gong W, Zhang C and Wang S: Epigallocatechin gallate inhibits the proliferation of colorectal cancer cells by regulating Notch signaling. Onco Targets Ther. 6:145–153. 2013. View Article : Google Scholar : PubMed/NCBI
20	Hoffman RM: Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs. 17:343–359. 1999. View Article : Google Scholar : PubMed/NCBI
21	Nishida N, Yano H, Nishida T, Kamura T and Kojiro M: Angiogenesis in cancer. Vasc Health Risk Manag. 2:213–219. 2006. View Article : Google Scholar
22	Shih T and Lindley C: Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 28:1779–1802. 2006. View Article : Google Scholar : PubMed/NCBI
23	Jiang BH and Liu LZ: AKT signaling in regulating angiogenesis. Curr Cancer Drug Targets. 8:19–26. 2008. View Article : Google Scholar : PubMed/NCBI
24	Manning BD and Cantley LC: AKT/PKB signaling: navigating downstream. Cell. 129:1261–1274. 2007. View Article : Google Scholar : PubMed/NCBI
25	Zarubin T and Han J: Activation and signaling of the p38 MAP kinase pathway. Cell Res. 15:11–18. 2005. View Article : Google Scholar : PubMed/NCBI
26	Shi Y and Gaestel M: In the cellular garden of forking paths: how p38 MAPKs signal for downstream assistance. Biol Chem. 383:1519–1536. 2002.PubMed/NCBI
27	Rudolf E, Kralova V, Rudolf K and John S: The role of p38 in irinotecan-induced DNA damage and apoptosis of colon cancer cells. Mutat Res. 741–742:27–34. 2013.PubMed/NCBI
28	Liu HF, Hu HC and Chao JI: Oxaliplatin down-regulates survivin by p38 MAP kinase and proteasome in human colon cancer cells. Chem Biol Interact. 188:535–545. 2010. View Article : Google Scholar : PubMed/NCBI
29	Mazzanti G, Menniti-Ippolito F, Moro PA, et al: Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol. 65:331–341. 2009. View Article : Google Scholar : PubMed/NCBI
30	Lambert JD, Kennett MJ, Sang S, Reuhl KR, Ju J and Yang CS: Hepatotoxicity of high oral dose (−)-epigallocatechin-3-gallate in mice. Food Chem Toxicol. 48:409–416. 2010.
31	Shimizu M, Deguchi A, Lim JT, Moriwaki H, Kopelovich L and Weinstein IB: (−)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res. 11:2735–2746. 2005.
32	Shimizu M, Shirakami Y, Sakai H, et al: EGCG inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular carcinoma cells. Cancer Lett. 262:10–18. 2008. View Article : Google Scholar : PubMed/NCBI
33	Yunos NM, Beale P, Yu JQ and Huq F: Synergism from the combination of oxaliplatin with selected phytochemicals in human ovarian cancer cell lines. Anticancer Res. 31:4283–4289. 2011.PubMed/NCBI
34	Yang XW, Wang XL, Cao LQ, et al: Green tea polyphenol epigallocatechin-3-gallate enhances 5-fluorouracil-induced cell growth inhibition of hepatocellular carcinoma cells. Hepatol Res. 42:494–501. 2012. View Article : Google Scholar : PubMed/NCBI
35	Wu H, Xin Y, Xu C and Xiao Y: Capecitabine combined with (−)-epigallocatechin-3-gallate inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts. Exp Ther Med. 3:650–654. 2012.
36	Shimizu M, Fukutomi Y, Ninomiya M, et al: Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study. Cancer Epidemiol Biomarkers Prev. 17:3020–3025. 2008. View Article : Google Scholar : PubMed/NCBI